You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

olverembatinib, CML-CP

Showing 1 - 25 of 1,531
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Olverembatinib, Chronic Myeloid Leukemia, Chronic Phase, Tyrosine Kinase Inhibitors Trial in Shenzhen (olverembatinib)

Recruiting
  • Olverembatinib
  • +2 more
  • Shenzhen, Guangdong, China
    Shenzhen Second People's Hospital
Jul 26, 2022

Chronic Myeloid Leukemia in Myeloid Blast Crisis, Chronic Myeloid Leukaemia Transformation, Chronic Myeloid Leukemia -

Recruiting
  • Chronic Myeloid Leukemia in Myeloid Blast Crisis
  • +3 more
  • based decitabine and olverembatinib（HQP1351)chemotherapy
  • Guanzhou, China
    Department of Hematology, Nanfang Hospital, Southern Medical Uni
Dec 6, 2022

Treatment Free Remission (TFR) in CML Patients (CML-CP)Study

Not yet recruiting
  • Chronic Myeloid Leukemia
  • Treatment-free Remission
  • TFR(Treatment-Free Remission)
  • (no location specified)
Jun 27, 2022

3rd Line Therapy or More to Treat Adult CML- CP in Real World

Not yet recruiting
  • Chronic Myeloid Leukemia
  • Asciminib
  • (no location specified)
Oct 16, 2023

Among CP-CML Participants Initiating Dasatinib inReal Life

Completed
  • Chronic Myeloid Leukemia
  • Non-Interventional
  • Paris, France
    Local Institution
Jun 17, 2022

Needs of 3L+ CP-CML and With T315I-mutated CML Patients

Completed
  • Chronic Myeloid Leukemia
  • 3L Therapy
  • T315I
  • Lyon, France
    Novartis Investigative Site
Nov 9, 2022

Flumatinib, Chronic Myeloid Leukemia, Chronic Phase, Imatinib Trial in Shenzhen (Flumatinib)

Recruiting
  • Flumatinib
  • +2 more
  • Shenzhen, Guangdong, China
    The Second People's Hospital of Shenzhen
Mar 15, 2022

Trial (Olverembatinib)

Available
    • (no location specified)
    Nov 10, 2022

    Withdrawal of Second-generation Tyrosine Kinase Inhibitors After

    Recruiting
    • MMR on 12 Month
    • Guangzhou, Guangdong, China
    • +1 more
    Apr 21, 2022

    Chronic Myeloid Leukemia in Chronic Phase Trial in Shenzhen (Flumatinib, Dasatinib)

    Recruiting
    • Chronic Myeloid Leukemia in Chronic Phase
    • Shenzhen, Guangdong, China
      Shenzhen Second People's Hospital
    Jul 26, 2022

    CML, Chronic Phase Trial in Harbin (Flumatinib, Imatinib)

    Not yet recruiting
    • CML, Chronic Phase
    • Harbin, Heilongjiang, China
      Institute of Hematology and Oncology, Harbin The First Hospital
    May 5, 2022

    Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Trial (Asciminib, Nilotinib)

    Not yet recruiting
    • Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
    • (no location specified)
    Jul 11, 2022

    Chronic Phase Chronic Myelogenous Leukemia Trial in Detroit, Milwaukee (Asciminib, Imatinib)

    Recruiting
    • Chronic Phase Chronic Myelogenous Leukemia
    • Detroit, Michigan
    • +1 more
    May 3, 2022

    Withdrawal or Reduction TKIs in CML-CP

    Recruiting
    • MMR on 12 Month
    • withdrawal TKIs or halve TKIs
    • Guangzhou, Guangdong, China
      NanfangH
    Sep 2, 2021

    Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission Trial (Asciminib, Imatinib)

    Not yet recruiting
    • Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission
    • (no location specified)
    Jun 7, 2022

    CML, Chronic Myelogenous Leukemia, Leukemia, Myeloid Chronic Trial in Worldwide (Asciminib add-on, Imatinib, Nilotinib)

    Recruiting
    • CML
    • +3 more
    • Asciminib add-on
    • +3 more
    • Augusta, Georgia
    • +46 more
    Jan 23, 2023

    Leukemia, Chronic Myelogenous Trial in China (asciminib, best available treatment)

    Recruiting
    • Leukemia, Chronic Myelogenous
    • Chongqing City, Chongqing, China
    • +23 more
    Jan 18, 2023

    CML, Philadelphia Chromosome Positive (Ph+), Chronic Myelogenous Leukemia Chronic Phase(CML-CP) Patients With Low Imatinib

    Terminated
    Has Results
    • CML
    • +2 more
    • Las Vegas, Nevada
    • +2 more
    Apr 28, 2021

    Flumatinib Versus Nilotinib for Chronic Phase Chronic Myeloid

    Recruiting
    • CML-CP; Mutation;Suboptimal Response or Failure in TKI
    • Wuhan, Hubei, China
      Weiming Li
    May 31, 2021

    Chronic Myeloid Leukemia, Chronic Phase, Nilotinib Trial in Shenzhen (Nilotinib)

    Recruiting
    • Chronic Myeloid Leukemia, Chronic Phase
    • Nilotinib
    • Shenzhen, Guangdong, China
      Shenzhen Second People's Hospital
    Mar 15, 2022

    Chronic Myelogenous Leukemia - Chronic Phase Trial in China (Dasatinib Tablets)

    Completed
    • Chronic Myelogenous Leukemia - Chronic Phase
    • Dasatinib Tablets
    • Shenzhen, Guangdong, China
    • +3 more
    Jun 11, 2021

    Chronic Myelogenous Leukemia Trial in Worldwide (ABL001 40mg BID, ABL001 80mg QD, ABL001 200mg QD)

    Recruiting
    • Chronic Myelogenous Leukemia
    • ABL001 40mg BID
    • +2 more
    • Caba, Buenos Aires, Argentina
    • +53 more
    Jan 27, 2023

    CML, Imatinib Trial in Seoul (high-dose imatinib)

    Completed
    • CML
    • Imatinib
    • high-dose imatinib
    • Seoul, Korea, Republic of
      Novartis Investigational Site
    Mar 9, 2021

    Early Conversion of Dasatinib in CML-CP Patients

    Enrolling by invitation
    • Validity and Safety
    • Dasatinib 100 MG
    • Guangzhou, Guangdong, China
      NanfangH
    Dec 9, 2020

    Chronic Myeloid Leukemia, Chronic Phase, CML, Chronic Phase, CML, Refractory Trial in Worldwide (Radotinib HCl)

    Recruiting
    • Chronic Myeloid Leukemia, Chronic Phase
    • +3 more
    • Radotinib HCl
    • Uijeongbu-si, Gyeonggi-do, Korea, Republic of
    • +17 more
    Jan 3, 2022